An investigation of the impact of futility analysis in publicly funded trials

Trials

Volumn 15, Issue 1, 2014, Pages

  Sully, Benjamin G O ^a   Julious, Steven A ^a   Nicholl, Jon ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adaptive designs; Efficiency; Futility; Health technology assessment; Medical research council; Recruitment

Indexed keywords

ARTICLE; CALCULATION; CLINICAL TRIAL (TOPIC); COST UTILITY ANALYSIS; EFFECT SIZE; FOLLOW UP; FUTILITY ANALYSIS; HUMAN; PUBLICLY FUNDED TRIAL; RETROSPECTIVE STUDY; SAMPLE SIZE; SECONDARY ANALYSIS; STUDY DESIGN;

CLINICAL TRIALS AS TOPIC; COST SAVINGS; COST-BENEFIT ANALYSIS; EARLY TERMINATION OF CLINICAL TRIALS; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MEDICAL FUTILITY; PUBLIC SECTOR; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84895537231     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-61     Document Type: Article

References (21)

1. Sully BG, Julious SA, Nicholl J. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. Trials 2013, 14:166. 10.1186/1745-6215-14-166, 3691846, 23758961.
2. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, Elbourne DR, Francis D, Garcia J, Roberts I, Snowdon C. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials 2006, 7:9. 10.1186/1745-6215-7-9, 1475627, 16603070.
3. Mahajan R, Gupta K. Adaptive design clinical trials: methodology, challenges and prospect. Indian J Pharmacol 2010, 42:201-207. 10.4103/0253-7613.68417, 2941608, 20927243.
4. Kaitin K. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther 2010, 87:356-361. 10.1038/clpt.2009.293, 2953249, 20130565.
5. Lamb S. Adaptive Designs 2010, Available at: http://www2.warwick.ac.uk/fac/med/research/hscience/ctu/about/news/adsd/sallie_lamb_-_encouraging_adaptive_designs_in_nihr_funded_research.ppt. Accessed 14 August 2013.
6. Dent L, Raftery J. Treatment success in pragmatic randomised controlled trials: a review of trials funded by the UK health technology assessment programme. Trials 2011, 12:109. 10.1186/1745-6215-12-109, 3113983, 21542934.
7. The VITATOPS, Hankey GJ, Algra A, Chen C, Wong MC, Cheung R, Wong L, Divjak I, Ferro J, de Freitas G, Gommans J, Groppa S, Hill M, Spence D, Lees K, Lisheng L, Navarro J, Ranawaka U, Ricci S, Schmidt R, Slivka A, Tan K, Tsiskaridze A, Uddin W, Vanhooren G, Xavier D, Armitage J, Hobbs M, Le M, Sudlow C, Wheatley K, Yi Q, Bulder M, Eikelboom JW, Hankey GJ, Ho WK, Jamrozik K, Klijn K, Koedam E, Langton P, , et al. Trial Study Group VITATOPS, the VITAmins TO Prevent Stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444). Int J Stroke 2007, 2:144-150. Trial Study Group.
8. Waterhouse JC, Walters SJ, Oluboyede Y, Lawson RA. A randomised 2 × 2 trial of community versus hospital pulmonary rehabilitation, followed by telephone or conventional follow-up. Health Technol Assess 2010, 14:1-140.
9. Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 2013, 14:199-209. 10.1016/S1470-2045(12)70600-9, 23395119.
10. Julious SA, Dimairo M. Discussion on the paper by Hampson and Jennison. J R Stat Soc Ser B Stat Methodol 2013, 75:40-41.
11. Jaki T. Uptake of novel statistical methods for early-phase clinical studies in the UK public sector. Clin Trials 2013, 10:344-346. 10.1177/1740774512474375, 23378484.
12. Proschan MA, Lan KK, Wittes J. Statistical Monitoring of Clinical Trials 2006, New York: Springer.
13. Jitlal M, Khan I, Lee SM, Hackshaw A. Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies. British Journal of Cancer 2012, 107:910-917. 10.1038/bjc.2012.344, 3464764, 22878376.
14. CLOTS Trials Collaboration Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet. 2009 Jun 6, 373(9679):1958-1965. CLOTS Trials Collaboration.
15. Lachin JM. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit. Clinical Trials 2009, 6:565-573. 10.1177/1740774509350327, 19933716.
16. Julious SA. Tutorial in biostatistics: sample sizes for clinical trials with normal data. Statistics in Medicine 2004, 23:1921-1986. 10.1002/sim.1783, 15195324.
17. Chang WH, Chuang-Stein C. Type I error and power in trials with one interim futility analysis. Pharm Stat 2004, 3:51-59.
18. ADDPLANTM 6 ADDPLAN, Inc an Aptiv Solutions company, ADDPLANTM 6.
19. Wang SK, Tsiatis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 1987, 43:193-199. 10.2307/2531959, 3567304.
20. Hampson LV, Jennison C. Group sequential tests for delayed responses (with discussion). J R Stat Soc Ser B Stat Methodol 2013, 75:3-54.
21. Sutton L, Julious SA, Goodacre SW. Influence of adaptive analysis on unnecessary patient recruitment: reanalysis of the RATPAC trial. Ann Emerg Med 2012, 60:442-448. e1, 10.1016/j.annemergmed.2012.03.032, 22632776.